Literature DB >> 12782430

Palliative care in a national cancer center: results in 1987 vs. 1993 vs. 2000.

Franco De Conno1, Cristina Panzeri, Cinzia Brunelli, Luigi Saita, Carla Ripamonti.   

Abstract

In the last few years, palliative care for advanced and terminal cancer patients has undergone considerable evolution. We determined the characteristics of patients admitted to the 4-bed Palliative Care Unit (PCU) of the National Cancer Institute (NCI) of Milan in 1987, 1993 and 2000 to evaluate how our diagnostic and therapeutic approaches have changed over the years. We reviewed the charts of every patient admitted to the PCU in 1987, 1993, and the first ten months of 2000. We recorded demographic data; the primary tumor sites; the main reason for admission; the types of therapies administered (oncologic, analgesic, surgical, neurosurgical analgesic procedures, and supportive therapy); the type and number of cardiological, radiological and endoscopic examinations, as well as specialist consultations; the duration of stay and eventual death on the Unit. There were no significant differences regarding gender, age, primary tumor site and death in hospital of the patients admitted during these years. The time spent in hospital increased over time (P = 0.006). A significant increase was observed in the percentage of patients admitted for supportive therapy (P < 0.001) and investigation concerning the stage of the disease (P < 0.001). There was a significant decrease in admission for invasive analgesic procedures (P < 0.001), as well as for pain diagnosis and/or uncontrolled pain. Uncontrolled pain remained the most frequent reason for admission. Over the years, during hospitalization, 7% to 12% of the patients underwent radiotherapy,1% to 9% had computerized tomography, and 4% to 8% had palliative surgery. More than 50% of the patients received intravenous hydration; a few patients received hypodermoclysis in 1987. Over time, there was a significant increase in "as needed" administration of nonsteroidal anti-inflammatory drugs and a significant reduction in their regular administration (from 24% in 1987 and 1993 to 3% in 2000) (P < 0.001). The use of codeine, tramadol and methadone increased (P < 0.001), whereas the use of oral morphine, buprenorphine and oxycodone decreased in 2000 (P < 0.001). There was a reduction in the use of antidepressants (no significant constant trend) and a significant increase in the use of anticonvulsants, laxatives and pamidronate (P < 0.001). Regularly administered hypnotics decreased in 1993 and increased in 2000 (P < 0.001). Over these years, no significant differences were found in the routes of opioid administration, in route switching and in the mean maximum oral opioid dose (ranging from 108 to 126 mg/day). The percentage of patients undergoing percutaneous cordotomy significantly decreased in 1993 and 2000 (P < 0.001). Over time, there was an increase in requests for specialist consultations, which was significant for neurological, cardiological and oncological consults (P < 0.001). Although the characteristics of the patients admitted to the PCU did not change over these years, there have been significant modifications in our therapeutic approaches, above all in the use of supportive therapy, adjuvant drugs, opioids and neurosurgical invasive procedures. Moreover, a major collaborative interaction with other specialists of the NCI took place with the aim to tailor treatment for each single patient.

Entities:  

Mesh:

Year:  2003        PMID: 12782430     DOI: 10.1016/s0885-3924(03)00069-1

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  6 in total

1.  Cardiovascular risk assessment in cancer patients undergoing major surgery.

Authors:  Daniel A Pryma; Gregory Ravizzini; David Amar; Virginia L Richards; Jigar B Patel; H William Strauss
Journal:  J Nucl Cardiol       Date:  2005 Mar-Apr       Impact factor: 5.952

Review 2.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

3.  Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability.

Authors:  Emilia Barcia; Alicia Martín; María Luz Azuara; Yolanda Sánchez; Sofia Negro
Journal:  Support Care Cancer       Date:  2006-07-18       Impact factor: 3.603

4.  Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.

Authors:  Barbara Silvestri; Elena Bandieri; Salvatore Del Prete; Giovanni Pietro Ianniello; Giuseppe Micheletto; Mario Dambrosio; Giovanni Sabbatini; Luigi Endrizzi; Alessandro Marra; Enrico Aitini; Angioletta Calorio; Ferdinando Garetto; Giuseppe Nastasi; Francovito Piantedosi; Vincenzo Sidoti; Piergiorgio Spanu
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 5.  Codeine, alone and with paracetamol (acetaminophen), for cancer pain.

Authors:  Carmen Straube; Sheena Derry; Kenneth C Jackson; Philip J Wiffen; Rae F Bell; Scott Strassels; Sebastian Straube
Journal:  Cochrane Database Syst Rev       Date:  2014-09-19

6.  Availability of and factors related to interventional procedures for refractory pain in patients with cancer: a nationwide survey.

Authors:  Yuko Uehara; Yoshihisa Matsumoto; Toshifumi Kosugi; Miyuki Sone; Naoki Nakamura; Akio Mizushima; Mitsunori Miyashita; Tatsuya Morita; Takuhiro Yamaguchi; Eriko Satomi
Journal:  BMC Palliat Care       Date:  2022-09-26       Impact factor: 3.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.